Since the first Hetao International Pharmaceutical Forum was successfully held on May 13, 2021, Dr. Du Tao, chairman of Shenzhen Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Pharmaceutics"), as the initiator of the forum, has been paying close attention to the development of Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Hetao as shenzhen and Hong Kong "bite" is extremely conducive to Chinese enterprises and international docking. At the same time, the drug audit center will be located here in the future to facilitate the development of innovative pharmaceutical research and development enterprises. Therefore, Dr. Du Tao believes that Evergreen, which has strong ability of drug innovation and development, should enter Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone as soon as possible to carry out international industrialization layout.

Picture 1: Futian International Biomedical Industrial Park

To this end, Evergreen opened the Hetao Laboratory on November 10, 2021. The laboratory is located in Shenzhen Futian Biomedical R&D public service platform. The platform will be managed by Shenzhen Borui Pharmaceutics Technology Co., LTD. (hereinafter referred to as "Borui Pharmaceutical"), a subsidiary of listed Boji Pharmaceutical Technology Co., LTD. Evergreen pharmaceutics will accelerate preclinical drug development with the help of Borui Pharmaceutics and its R&D service platform, providing a large amount of scientific evidence for patent and clinical application of pipeline drugs. At the same time, Evergreen will continue to expand the experimental research and development team from this laboratory, and train more scientific and technological talents in pharmacology, efficacy, pharmaceutics and preparations for the enterprise, so as to ensure the sustainable development of Evergreen innovation.

Picture 2: The opening ceremony of the Evergreen Pharmaceutics Laboratory

The opening ceremony of Evergreen Hetao Laboratory was attended by COO Wang Zhuo, Senior Vice President Yang Yihang, Director of Pharmacology Dr. Hu Tao and General Manager of Bo Rui Dr. Zuo Lian. In the future, the two companies will carry out more business cooperation in the Hetao region and expect eglin to have greater development in drug innovation research and development.

Picture 3: Evergreen teams visited  Borui Pharmaceutics